From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors

被引:27
作者
Gardner, Christopher R. [1 ,2 ]
Davies, Katherine A. [1 ,2 ]
Zhang, Ying [1 ,2 ]
Brzozowski, Martin [1 ,2 ,3 ]
Czabotar, Peter E. [1 ,2 ]
Murphy, James M. [1 ,2 ]
Lessene, Guillaume [1 ,2 ,4 ]
机构
[1] Walter & Eliza Hall Inst Med Res, Parkville, VIC 3052, Australia
[2] Univ Melbourne, Dept Med Biol, Parkville, VIC 3052, Australia
[3] Bio21 Inst, 30 Flemington Rd, Parkville, VIC 3052, Australia
[4] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, VIC 3052, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
MIXED-LINEAGE KINASE; DOMAIN-LIKE PROTEIN; CELL-DEATH; PSEUDOKINASE MLKL; HIGHLY POTENT; CHEMICAL INHIBITOR; CASPASE INHIBITOR; DISTINCT ROLES; DISCOVERY; RIPK3;
D O I
10.1021/acs.jmedchem.2c01621
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Necroptosis is a regulated caspase-independent form of necrotic cell death that results in an inflammatory phenotype. This process contributes profoundly to the pathophysiology of numerous neurodegenerative, cardiovascular, infectious, malignant, and inflammatory diseases. Receptor-interacting protein kinase 1 (RIPK1), RIPK3, and the mixed lineage kinase domain-like protein (MLKL) pseudokinase have been identified as the key components of necroptosis signaling and are the most promising targets for therapeutic intervention. Here, we review recent developments in the field of small-molecule inhibitors of necroptosis signaling, provide guidelines for their use as chemical probes to study necroptosis, and assess the therapeutic challenges and opportunities of such inhibitors in the treatment of a range of clinical indications.
引用
收藏
页码:2361 / 2385
页数:25
相关论文
共 50 条
[41]   Necroptosis: A Novel Cell Death Modality and Its Potential Relevance for Critical Care Medicine [J].
Moreno-Gonzalez, Gabriel ;
Vandenabeele, Peter ;
Krysko, Dmitri V. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 194 (04) :415-428
[42]   Mitophagy as a mitochondrial quality control mechanism in myocardial ischemic stress: from bench to bedside [J].
Fu, Tong ;
Ma, Yanchun ;
Li, Yan ;
Wang, Yingwei ;
Wang, Qi ;
Tong, Ying .
CELL STRESS & CHAPERONES, 2023, 28 (03) :239-251
[43]   The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside [J].
Li, Yukun ;
Lin, Rong ;
Peng, Xiaodong ;
Wang, Xuesi ;
Liu, Xinmeng ;
Li, Linling ;
Bai, Rong ;
Wen, Songnan ;
Ruan, Yanfei ;
Chang, Xing ;
Tang, Ribo ;
Liu, Nian .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
[44]   The multifaceted perspectives on the regulation of lncRNAs in hepatocellular carcinoma ferroptosis: from bench-to-bedside [J].
Jin, Xin ;
Huang, Chun Xia ;
Tian, Yue .
CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
[45]   Beyond Bench and Bedside: Disentangling the Concept of Translational Research [J].
van der Laan, Anna Laura ;
Boenink, Marianne .
HEALTH CARE ANALYSIS, 2015, 23 (01) :32-49
[46]   Bench-to-Bedside Studies of Arginine Deprivation in Cancer [J].
Field, George C. ;
Pavlyk, Iuliia ;
Szlosarek, Peter W. .
MOLECULES, 2023, 28 (05)
[47]   Current translational potential and underlying molecular mechanisms of necroptosis [J].
Molnar, Tamas ;
Mazlo, Anett ;
Tslaf, Vera ;
Szollosi, Attila Gabor ;
Emri, Gabriella ;
Koncz, Gabor .
CELL DEATH & DISEASE, 2019, 10 (11)
[48]   Exploring necroptosis: mechanistic analysis and antitumor potential of nanomaterials [J].
Dong, Jiaheng ;
Zhang, Jiale ;
Yao, Kunhou ;
Xu, Xiao ;
Zhou, Yaqi ;
Zhang, Lei ;
Qin, Changjiang .
CELL DEATH DISCOVERY, 2025, 11 (01)
[49]   Necroptosis in Organ Transplantation: Mechanisms and Potential Therapeutic Targets [J].
Zhao, Yajin ;
Main, Kimberly ;
Aujla, Tanroop ;
Keshavjee, Shaf ;
Liu, Mingyao .
CELLS, 2023, 12 (18)
[50]   Knowledge Mapping of Necroptosis From 2012 to 2021: A Bibliometric Analysis [J].
Zhang, Jie ;
Song, Luxia ;
Jia, Jundi ;
Tian, Wende ;
Lai, Runmin ;
Zhang, Zihao ;
Li, Jingen ;
Ju, Jianqing ;
Xu, Hao .
FRONTIERS IN IMMUNOLOGY, 2022, 13